anti cancer medicine

Keytruda Injection (Pembrolizumab): Breakthrough PD-1 Immunotherapy – Global Supply by Ernest Oncology In the rapidly advancing oncology landscape of 2026, Keytruda (Pembrolizumab) stands as the definitive leader in immune checkpoint inhibition. As a humanized monoclonal antibody, Keytruda targets the Programmed Death-1 (PD-1) receptor, effectively “releasing the brakes“ on the body's immune system to identify and destroy cancer cells across a vast range of clinical indications. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the international distribution of Keytruda to the USA, UK, London, Abu Dhabi, Australia, and South Africa, providing validated cold-chain logistics and comprehensive pharmaceutical documentation. Technical Product Profile: Keytruda (Pembrolizumab) 100mg/4mL Keytruda is supplied as a sterile, preservative-free, clear to slightly opalescent, colorless to pale-yellow solution for intravenous (IV) infusion. Product Specifications Active Ingredient: Pembrolizumab. Concentration: 25 mg/mL (Standard 100 mg/4 mL single-dose vial). Mechanism of Action: PD-1 Blocking Antibody; inhibits the interaction between PD-1 and its ligands (PD-L1 and PD-L2), reactivating tumor-specific cytotoxic T-lymphocytes. Therapeutic Class: Antineoplastic / Immunotherapy (Checkpoint Inhibitor). Storage Requirements: Must be maintained in a strictly monitored cold chain at 2°C to 8°C (36°F to 46°F). Protect from light; do not freeze or shake. Primary Clinical Indications Keytruda is uniquely versatile, with approvals for dozens of indications, including: Melanoma: Adjuvant treatment and metastatic cases. Non-Small Cell Lung Cancer (NSCLC): First-line treatment (monotherapy or combination). Head and Neck Squamous Cell Carcinoma (HNSCC): Recurrent or metastatic. Urothelial Carcinoma: For patients ineligible for cisplatin-containing chemotherapy. MSI-H or dMMR Cancers: Solid tumors that have progressed following prior treatment. Renal Cell Carcinoma (RCC): In combination with axitinib or lenvatinib. Key Features & Global Logistics Excellence Pioneering Immunotherapy: Keytruda is the standard-of-care for multiple tumor types, offering significant improvements in overall survival (OS) and progression-free survival (PFS). Broad-Spectrum Efficacy: Effective against both PD-L1 positive and negative tumors depending on the clinical setting. Validated Cold-Chain Shipping: Ernest Oncology utilizes IATA-certified, temperature-controlled packaging and real-time monitoring to ensure the biologic integrity of Keytruda during transit to London, Abu Dhabi, or Sydney. Regulatory Precision: Every shipment includes a Certificate of Analysis (CoA) and adheres to international Good Distribution Practices (GDP), ensuring smooth customs clearance in strictly regulated Tier-1 markets. Global Export Reach: USA, UK, UAE, Australia, & South Africa Ernest Oncology manages the complex regulatory requirements for exporting specialized biologics from India to major global healthcare hubs: USA: Supplying specialized oncology centers and B2B wholesale distributors with high-quality Pembrolizumab. UK & London: Supporting the NHS and private oncology clinics with reliable, consistent access to immunotherapy. Abu Dhabi, UAE: Catering to the advanced medical networks and specialized hospitals of the Middle East with rapid, secure delivery. Australia: Navigating TGA (Therapeutic Goods Administration) standards to provide Australian healthcare providers with essential cancer medications. South Africa: Strengthening the Southern African oncology sector through consistent bulk supply and competitive pricing. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of Keytruda and specialized oncology medications. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Reditux Injection (Rituximab): High-Quality CD20 Biosimilar – Global Supply by Ernest Oncology In the value-driven healthcare landscape of 2026, Reditux (Rituximab) has established itself as one of the world's most trusted biosimilars for the treatment of B-cell malignancies and autoimmune disorders. Manufactured by Dr. Reddy’s Laboratories, Reditux is a chimeric monoclonal antibody that targets the CD20 antigen on B-lymphocytes. By providing a clinically equivalent alternative to the reference biologic, Reditux significantly expands patient access to life-saving immunotherapy worldwide. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the international distribution of Reditux to the USA, UK, London, Abu Dhabi, Australia, and South Africa, providing validated cold-chain logistics and comprehensive pharmaceutical documentation. Technical Product Profile: Reditux (Rituximab) 100mg & 500mg Reditux is produced using advanced recombinant DNA technology and is supplied as a sterile, preservative-free concentrate for intravenous (IV) infusion. It is recognized for its rigorous similarity to the innovator molecule in terms of safety, purity, and potency. Product Specifications Active Ingredient: Rituximab (Biosimilar). Manufacturer: Dr. Reddy’s Laboratories Ltd. Concentration: 10 mg/mL (Available in 100 mg/10 mL and 500 mg/50 mL vials). Mechanism of Action: Binds specifically to the transmembrane antigen CD20; mediates B-cell lysis through complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). Therapeutic Class: Antineoplastic / Monoclonal Antibody. Storage Requirements: Must be maintained in a strictly monitored cold chain at 2°C to 8°C. Do not freeze or shake. Primary Clinical Indications Non-Hodgkin’s Lymphoma (NHL): Effective for follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Chronic Lymphocytic Leukemia (CLL): Used in combined chemo-immunotherapy regimens. Rheumatoid Arthritis (RA): For patients with inadequate response to one or more TNF-antagonists. Granulomatosis with Polyangiitis (GPA): Induction and maintenance of remission in adult and pediatric patients. Why Source Reditux via Ernest Oncology? Proven Biosimilarity: Reditux is backed by extensive clinical trials and real-world evidence, ensuring identical therapeutic outcomes to the innovator. Cost-Efficient Procurement: As a biosimilar, Reditux offers a more sustainable pricing model for hospital procurement and bulk distribution without compromising quality. Validated Cold-Chain Shipping: Ernest Oncology utilizes IATA-certified, temperature-controlled packaging to ensure the biologic integrity of Reditux during transit to London, Abu Dhabi, or Sydney. Global Compliance: Every shipment is accompanied by a Certificate of Analysis (CoA) and adheres to international Good Distribution Practices (GDP), ensuring seamless customs clearance. Global Distribution Reach: USA, UK, UAE, Australia, & South Africa Ernest Oncology excels in managing the complex regulatory requirements for exporting specialized biosimilars from India to major global healthcare hubs: USA: Reliable supply for oncology clinics and pharmaceutical wholesalers seeking high-quality biosimilar alternatives. UK & London: Supporting the NHS and private oncology networks with consistent access to CD20-directed therapies. Abu Dhabi, UAE: Rapid delivery to the advanced clinical infrastructure and specialized hospitals of the Middle East. Australia: Navigating TGA standards to provide Australian healthcare providers with authentic Rituximab biosimilars. South Africa: Strengthening the Southern African oncology sector through consistent bulk supply and competitive pricing. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of Reditux and specialized oncology medications. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Rituxan Injection (Rituximab): Targeted CD20 Antibody Therapy – Global Supply by Ernest Oncology In the advanced clinical landscape of 2026, Rituxan (Rituximab) remains a foundational biologic for the treatment of B-cell malignancies and various autoimmune disorders. As a genetically engineered chimeric monoclonal antibody, Rituxan specifically targets the CD20 antigen found on the surface of both normal and malignant B-lymphocytes. This targeted binding triggers a powerful immune response, leading to the depletion of problematic B-cells while allowing the body to regenerate a healthy immune population. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the international distribution of Rituxan to the USA, UK, London, Abu Dhabi, Australia, and South Africa, providing validated cold-chain logistics and comprehensive pharmaceutical documentation. Technical Product Profile: Rituxan (Rituximab) 100mg & 500mg Rituxan is supplied as a sterile, preservative-free, clear, and colorless liquid concentrate for intravenous (IV) infusion. It is recognized globally for its high efficacy in both oncology and rheumatology. Product Specifications Active Ingredient: Rituximab. Concentration: 10 mg/mL (available in 100 mg/10 mL and 500 mg/50 mL vials). Mechanism of Action: CD20-directed cytolytic antibody; mediates B-cell lysis via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). Therapeutic Class: Antineoplastic Monoclonal Antibody / B-cell Depletor. Storage Requirements: Must be stored in a specialized cold chain at 2°C to 8°C. Protect vials from direct light. Do not freeze or shake. Primary Clinical Indications Non-Hodgkin’s Lymphoma (NHL): Including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Chronic Lymphocytic Leukemia (CLL): Used in combination with fludarabine and cyclophosphamide. Rheumatoid Arthritis (RA): Indicated for adult patients with inadequate response to TNF-antagonists. Pemphigus Vulgaris (PV): A leading treatment for moderate to severe B-cell mediated skin conditions. Granulomatosis with Polyangiitis (GPA): Used for induction and maintenance of remission. Key Features & Global Logistics Excellence Precision B-Cell Targeting: Rituxan specifically depletes CD20+ B-cells while sparing hematopoietic stem cells, facilitating immune recovery post-therapy. Established Safety Profile: Backed by decades of clinical data, making it a trusted choice for oncology departments worldwide. Validated Cold-Chain Shipping: Ernest Oncology utilizes IATA-certified, temperature-controlled packaging to ensure the biologic integrity of Rituximab during transit to London, Abu Dhabi, or Sydney. Global Compliance: Every shipment is accompanied by a Certificate of Analysis (CoA) and adheres to international Good Distribution Practices (GDP). Global Export Reach: USA, UK, UAE, Australia, & South Africa Ernest Oncology excels in managing the complex regulatory requirements for exporting targeted biological therapies from India to major global healthcare hubs. USA: Supplying specialized oncology centers and B2B wholesale distributors with high-quality Rituximab vials. UK & London: Supporting the NHS and private oncology clinics with reliable, cost-effective access to monoclonal antibodies. Abu Dhabi, UAE: Catering to the advanced medical networks and specialized hospitals of the Middle East with rapid, secure biologic delivery. Australia: Navigating TGA (Therapeutic Goods Administration) standards to provide Australian healthcare providers with essential cancer medications. South Africa: Strengthening the Southern African oncology sector through consistent bulk supply and competitive pricing. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of Rituxan and specialized oncology medications. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

MabThera Injection (Rituximab): Targeted CD20 Antibody Therapy – Global Supply by Ernest Oncology In the advanced clinical landscape of 2026, MabThera (Rituximab) remains a foundational biologic for the treatment of various B-cell malignancies and autoimmune conditions. As a genetically engineered chimeric mouse/human monoclonal antibody, MabThera specifically targets the CD20 antigen found on the surface of normal and malignant B-lymphocytes. Upon binding, it initiates a powerful immune response that leads to B-cell lysis. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the international distribution of MabThera to the USA, UK, London, Abu Dhabi, Australia, and South Africa, providing validated cold-chain logistics and comprehensive pharmaceutical documentation. Technical Product Profile: MabThera (Rituximab) 100mg/500mg MabThera is supplied as a sterile, preservative-free, clear, and colorless liquid concentrate for intravenous (IV) infusion. It is also available in some markets as a subcutaneous (SC) formulation. Product Specifications Active Ingredient: Rituximab. Concentration: 10mg/mL (available in 100mg/10mL and 500mg/50mL vials). Mechanism of Action: CD20-directed cytolytic antibody; mediates B-cell lysis via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). Therapeutic Class: Antineoplastic Monoclonal Antibody. Storage Requirements: Must be stored in a specialized cold chain at 2°C to 8°C. Protect vials from direct light. Do not freeze or shake. Primary Clinical Indications Non-Hodgkin’s Lymphoma (NHL): Including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Chronic Lymphocytic Leukemia (CLL): Typically used in combination with chemotherapy (e.g., fludarabine and cyclophosphamide). Rheumatoid Arthritis (RA): In combination with methotrexate for adult patients with inadequate response to TNF-antagonists. Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA). Key Features & Global Logistics Excellence High-Precision Targeting: MabThera specifically depletes B-cells while sparing hematopoietic stem cells, allowing the immune system to regenerate healthy B-cells post-treatment. Multi-Indication Efficacy: A versatile biologic with proven results in both oncology and high-level immunology. Validated Cold-Chain Shipping: Ernest Oncology utilizes IATA-certified, temperature-controlled packaging to ensure the biologic integrity of Rituximab during transit to London, Abu Dhabi, or Sydney. Global Compliance: Every shipment is accompanied by a Certificate of Analysis (CoA) and adheres to international Good Distribution Practices (GDP). Global Export Reach: USA, UK, UAE, Australia, & South Africa Ernest Oncology excels in managing the complex regulatory requirements for exporting targeted biological therapies from India to major global healthcare hubs. USA: Supplying specialized oncology centers and wholesale distributors with high-quality Rituximab vials. UK & London: Supporting the NHS and private oncology clinics with reliable, cost-effective access to monoclonal antibodies. Abu Dhabi, UAE: Catering to the advanced medical networks and specialized hospitals of the Middle East with rapid, secure biologic delivery. Australia: Navigating TGA (Therapeutic Goods Administration) standards to provide Australian oncology departments with essential cancer and immunology medications. South Africa: Strengthening the Southern African oncology sector through consistent bulk supply and competitive pricing. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of MabThera and specialized oncology medications. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Panitumumab Injection: Advanced EGFR Targeting for mCRC – Global Supply by Ernest Oncology In the precision-driven oncology landscape of 2026, Panitumumab remains a critical biologic therapy for patients with wild-type RAS metastatic colorectal cancer (mCRC). As the first fully human monoclonal antibody to target the epidermal growth factor receptor (EGFR), Panitumumab offers a high-affinity intervention that disrupts the signaling pathways essential for tumor cell survival and proliferation. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the international distribution of Panitumumab to the USA, UK, London, Abu Dhabi, Australia, and South Africa, providing validated cold-chain logistics and comprehensive regulatory documentation. Technical Product Profile: Panitumumab 20mg/mL Panitumumab is a sterile, preservative-free solution for intravenous (IV) infusion. Its “fully human“ molecular structure is designed to reduce the risk of infusion-related reactions compared to chimeric antibodies. Product Specifications Active Ingredient: Panitumumab. Concentration: 20 mg/mL (available in 100 mg/5 mL and 400 mg/20 mL single-dose vials). Mechanism of Action: EGFR Inhibitor; binds to the EGFR on both normal and tumor cells, competitively inhibiting the binding of ligands. Therapeutic Class: Recombinant Fully Human IgG2 Monoclonal Antibody. Storage Requirements: Must be refrigerated at 2°C to 8°C. Do not freeze. Protect vials from direct light. Primary Clinical Indications Metastatic Colorectal Cancer (mCRC): Indicated as first-line treatment in combination with FOLFOX, or as monotherapy following disease progression in patients with wild-type RAS (both KRAS and NRAS) tumors. RAS Testing Requirement: Efficacy is limited to patients with wild-type RAS; confirmed testing of exons 2, 3, and 4 is essential prior to initiation. Why Source Panitumumab via Ernest Oncology? Fully Human Precision: The fully human IgG2 structure minimizes immunogenicity, offering a favorable safety profile for long-term treatment cycles. Proven Survival Outcomes: Significant improvements in progression-free survival (PFS) when integrated into modern chemotherapy regimens. Validated Cold-Chain Shipping: Ernest Oncology utilizes IATA-compliant, temperature-monitored packaging to ensure Panitumumab maintains its biologic potency from India to London, Abu Dhabi, or Johannesburg. Global Export Expertise: We provide all necessary documentation, including Certificates of Analysis (CoA) and origin certificates, ensuring smooth customs clearance in strictly regulated markets. Global Distribution Reach: USA, UK, UAE, Australia, & South Africa We specialize in high-efficiency pharmaceutical exports to major international healthcare hubs: USA: Reliable procurement for specialized cancer centers and B2B pharmaceutical wholesalers. UK & London: Supporting NHS Trusts and private oncology networks with consistent supply of critical biologics. Abu Dhabi (UAE): Rapid delivery to the advanced clinical infrastructure and specialized hospitals of the Middle East. Australia: Navigating TGA-compliant pathways to supply Australian oncology departments with authentic medications. South Africa: Expanding access to high-tier targeted therapies across the Southern African medical sector. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of Panitumumab and specialized oncology medications. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Pamitum Injection (Panitumumab): Precision EGFR Inhibition for mCRC – Global Supply by Ernest Oncology In the rapidly advancing oncology sector of 2026, Pamitum (Panitumumab) stands as a vital therapeutic option for adult patients with wild-type RAS metastatic colorectal cancer (mCRC). As a recombinant, fully human IgG2 monoclonal antibody, Pamitum offers high-affinity binding to the epidermal growth factor receptor (EGFR), effectively halting the signaling cascades that drive tumor cell proliferation, survival, and angiogenesis. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure international distribution of Pamitum to the USA, UK, London, Abu Dhabi, Australia, and South Africa, providing validated cold-chain logistics and complete regulatory documentation. Technical Product Profile: Pamitum (Panitumumab) 100mg/5mL Pamitum is formulated as a sterile, preservative-free solution for intravenous (IV) infusion. Its fully human molecular structure is specifically engineered to reduce the incidence of infusion-related reactions often associated with chimeric antibodies. Product Specifications Active Ingredient: Panitumumab. Concentration: 20 mg/mL (Standard 100 mg/5 mL single-dose vial). Mechanism of Action: EGFR Antagonist; binds to the extracellular domain of EGFR to inhibit ligand-induced tyrosine kinase phosphorylation. Therapeutic Class: Targeted Biologic / Monoclonal Antibody. Storage Requirements: Must be maintained in a specialized cold chain at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. Protect from direct sunlight. Primary Clinical Indications Metastatic Colorectal Cancer (mCRC): Indicated as a first-line treatment in combination with FOLFOX or as monotherapy following disease progression in patients with confirmed wild-type RAS (KRAS and NRAS) status. Biomarker Necessity: Use is strictly indicated for patients whose tumors do not harbor mutations in exons 2, 3, and 4 of KRAS and NRAS. Why Source Pamitum via Ernest Oncology? Fully Human Antibody Precision: The IgG2 structure offers a favorable safety profile, minimizing immunogenicity and improving patient tolerance during long-term treatment cycles. Proven Therapeutic Efficacy: Significant improvements in progression-free survival (PFS) when utilized in modern oncology regimens. Validated Cold-Chain Excellence: Ernest Oncology employs IATA-certified, temperature-monitored packaging to ensure Pamitum maintains its biologic potency from India to London, Abu Dhabi, or Sydney. Global Compliance: Every shipment includes a Certificate of Analysis (CoA) and adheres to international Good Distribution Practices (GDP), ensuring seamless customs clearance in highly regulated markets. Global Distribution Reach: USA, UK, UAE, Australia, & South Africa We specialize in high-efficiency pharmaceutical exports to major international healthcare hubs: USA: Reliable procurement for specialized cancer centers and B2B pharmaceutical wholesalers. UK & London: Supporting NHS Trusts and private oncology networks with consistent supply of critical biologics. Abu Dhabi (UAE): Rapid delivery to the advanced clinical infrastructure and hospitals of the Middle East. Australia: Navigating TGA-compliant pathways to supply Australian oncology departments with authentic medications. South Africa: Expanding access to high-tier targeted therapies across the Southern African medical sector. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of Pamitum and specialized oncology medications. 🌐 Websites:www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Vectibix Injection (Panitumumab): Advanced EGFR Targeting for mCRC – Global Supply by Ernest Oncology In the precision-driven oncology landscape of 2026, Vectibix (Panitumumab) remains a critical biologic therapy for patients with wild-type RAS metastatic colorectal cancer (mCRC). As the first fully human monoclonal antibody to target the epidermal growth factor receptor (EGFR), Vectibix offers a high-affinity intervention that disrupts the signaling pathways essential for tumor cell survival and proliferation. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the international distribution of Vectibix to the USA, UK, London, Abu Dhabi, Australia, and South Africa, providing validated cold-chain logistics and comprehensive regulatory documentation. Technical Product Profile: Vectibix (Panitumumab) 20mg/mL Vectibix is a sterile, preservative-free solution for intravenous (IV) infusion. Its “fully human“ molecular structure is designed to reduce the risk of infusion-related reactions compared to chimeric antibodies. Product Specifications Active Ingredient: Panitumumab. Concentration: 20 mg/mL (available in 100 mg/5 mL and 400 mg/20 mL single-dose vials). Mechanism of Action: EGFR Inhibitor; binds to the EGFR on both normal and tumor cells, competitively inhibiting the binding of ligands. Therapeutic Class: Recombinant Fully Human IgG2 Monoclonal Antibody. Storage Requirements: Must be refrigerated at 2°C to 8°C. Do not freeze. Protect vials from direct light. Primary Clinical Indications Metastatic Colorectal Cancer (mCRC): Indicated as first-line treatment in combination with FOLFOX, or as monotherapy following disease progression in patients with wild-type RAS (both KRAS and NRAS) tumors. RAS Testing Requirement: Efficacy is limited to patients with wild-type RAS; confirmed testing is essential prior to initiation. Why Choose Vectibix via Ernest Oncology? Fully Human Precision: The fully human IgG2 structure minimizes immunogenicity, offering a favorable safety profile for long-term treatment cycles. Proven Survival Outcomes: Significant improvements in progression-free survival (PFS) when integrated into modern chemotherapy regimens. Validated Cold-Chain Shipping: Ernest Oncology utilizes IATA-compliant, temperature-monitored packaging to ensure Vectibix maintains its biologic potency from India to London, Abu Dhabi, or Johannesburg. Global Export Expertise: We provide all necessary documentation, including Certificates of Analysis (CoA) and origin certificates, ensuring smooth customs clearance in strictly regulated markets. Global Distribution Reach: USA, UK, UAE, Australia, & South Africa We specialize in high-efficiency pharmaceutical exports to major international healthcare hubs: USA: Reliable procurement for specialized cancer centers and B2B pharmaceutical wholesalers. UK & London: Supporting NHS Trusts and private oncology networks with consistent supply of critical biologics. Abu Dhabi (UAE): Rapid delivery to the advanced clinical infrastructure of the Middle East. Australia: Navigating TGA-compliant pathways to supply Australian oncology departments with authentic medications. South Africa: Expanding access to high-tier targeted therapies across the Southern African medical sector. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of Vectibix and specialized oncology medications. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Erbitux Injection (Cetuximab): Targeted EGFR Inhibitor Therapy – Global Supply by Ernest Oncology In the advanced oncological landscape of 2026, Erbitux (Cetuximab) remains a cornerstone biologic for the treatment of RAS wild-type metastatic colorectal cancer (mCRC) and squamous cell carcinoma of the head and neck (SCCHN). As a recombinant human/mouse chimeric monoclonal antibody, Erbitux specifically binds to the epidermal growth factor receptor (EGFR), effectively inhibiting tumor cell growth and induction of apoptosis. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the international distribution of Erbitux to the USA, UK, London, Abu Dhabi, Australia, and South Africa, providing validated cold-chain logistics and comprehensive pharmaceutical documentation. Technical Product Profile: Erbitux (Cetuximab) 5mg/mL Erbitux is supplied as a sterile, colorless liquid for intravenous (IV) infusion, requiring precision handling and strict temperature maintenance. Product Specifications Active Ingredient: Cetuximab. Concentration: 5 mg/mL (available in 100 mg/20 mL and 500 mg/100 mL vials). Mechanism of Action: EGFR Antagonist; binds to the extracellular domain of EGFR to block ligand-induced phosphorylation. Therapeutic Class: Monoclonal Antibody (Antineoplastic Agent). Storage Requirements: Must be refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. Primary Clinical Indications Metastatic Colorectal Cancer (mCRC): Indicated for RAS wild-type, EGFR-expressing mCRC as a single agent or in combination with chemotherapy (FOLFIRI/FOLFOX). Head and Neck Cancer (SCCHN): Used in combination with radiation therapy for locally advanced disease or with platinum-based therapy for metastatic cases. Key Features & Global Logistics Excellence Precision Targeting: Erbitux specifically inhibits the overexpressed EGFR pathways found in various solid tumors, minimizing damage to non-EGFR-expressing cells. Synergistic Efficacy: Proven to enhance the effectiveness of standard radiotherapy and cytotoxic chemotherapy regimens. Validated Cold-Chain Shipping: Ernest Oncology utilizes IATA-certified temperature-controlled packaging to ensure the biologic integrity of Erbitux during transit to London, Abu Dhabi, or Sydney. Global Compliance: Every shipment is accompanied by a Certificate of Analysis (CoA) and adheres to international Good Distribution Practices (GDP). Global Export Reach: USA, UK, UAE, Australia, & South Africa Ernest Oncology excels in managing the complex regulatory requirements for exporting targeted biological therapies from India to major global healthcare hubs. USA: Supplying specialized oncology centers and wholesale distributors with high-quality Cetuximab vials. UK & London: Supporting the NHS and private oncology clinics with reliable, cost-effective access to monoclonal antibodies. Abu Dhabi, UAE: Catering to the advanced medical networks of the Middle East with rapid, secure biologic delivery. Australia: Navigating TGA standards to provide Australian oncology departments with essential cancer medications. South Africa: Strengthening the Southern African oncology sector through consistent bulk supply and competitive pricing. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of Erbitux and specialized oncology medications. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Zybev Injection (Bevacizumab): Premium Anti-Angiogenic Biological Therapy – Global Supply by Ernest Oncology In the evolving oncology landscape of 2026, Zybev Injection (active ingredient Bevacizumab) has solidified its position as a critical biosimilar for the management of advanced solid tumors. As a recombinant humanized monoclonal antibody, Zybev provides clinical efficacy equivalent to the reference biologic, targeting the Vascular Endothelial Growth Factor (VEGF) to inhibit tumor-induced angiogenesis and arrest cancer progression. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Zybev to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring meticulous cold-chain management and rapid global delivery. Technical Product Profile: Zybev (Bevacizumab) Zybev is a biological therapy administered via intravenous (IV) infusion, designed to disrupt the blood supply that tumors require to grow and metastasize. Product Specifications Active Ingredient: Bevacizumab (Biosimilar) Available Strengths: 100 mg / 4 mL and 400 mg / 16 mL Single-dose Vials Pharmacological Class: Vascular Endothelial Growth Factor (VEGF) Inhibitor; Monoclonal Antibody Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Primary Clinical Indications Metastatic Colorectal Cancer (mCRC): Used as a foundational treatment in combination with fluoropyrimidine-based chemotherapy. Non-Small Cell Lung Cancer (NSCLC): First-line treatment for unresectable, locally advanced, recurrent, or metastatic non-squamous NSCLC. Glioblastoma: For the treatment of recurrent glioblastoma in adult patients. Metastatic Renal Cell Carcinoma (mRCC): In combination with interferon alfa. Ovarian & Cervical Cancers: Effective in persistent, recurrent, or metastatic cases when combined with specific chemotherapy regimens. Mechanism of Action: The Anti-Angiogenic Approach Zybev works by selectively binding to the VEGF protein, preventing it from interacting with its receptors on the surface of endothelial cells. Angiogenesis Inhibition: By neutralizing VEGF, Zybev prevents the formation of new blood vessels that tumors need for nutrients and oxygen. Vascular Regression: Existing tumor microvasculature undergoes regression, inhibiting tumor growth. Vascular Normalization: It helps normalize the remaining tumor vasculature, reducing interstitial fluid pressure and potentially improving the delivery of co-administered chemotherapy. Global Export Excellence: UK, USA, UAE, Australia, & South Africa Ernest Oncology specializes in navigating the strict regulatory and logistical requirements for shipping temperature-sensitive biosimilars from India to major international hubs. United Kingdom & London: We supply NHS trusts and private oncology clinics in London, adhering to all MHRA biological import protocols. United States: Bulk supply for hospital networks and specialty wholesalers seeking cost-effective, high-quality Bevacizumab biosimilars from India. Abu Dhabi & UAE: Supporting the UAE’s world-class healthcare sector with fast-track, secure, temperature-monitored shipping. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological standards. South Africa: Strengthening the African oncology sector with high-quality, cost-effective targeted therapies from GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of oncology biologics and anti-angiogenic biosimilars. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Pertuzumab Injection: Advanced HER2-Dimerization Inhibitor for Targeted Oncology – Global Supply by Ernest Oncology In the precision medicine landscape of 2026, Pertuzumab Injection remains a cornerstone in the treatment of Human Epidermal Growth Factor Receptor 2 (HER2) positive malignancies. As a recombinant humanized monoclonal antibody, Pertuzumab represents a sophisticated class of targeted therapy—HER2-dimerization inhibitors (HDIs)—designed to disrupt the signaling pathways that drive aggressive tumor proliferation. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Pertuzumab to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, providing end-to-end cold-chain solutions and rigorous documentation for global medical procurement. Technical Product Profile: Pertuzumab Injection Pertuzumab is a biological agent that targets the extracellular domain of the HER2 protein, specifically preventing it from pairing with other members of the HER family. Product Specifications Active Ingredient: Pertuzumab Concentration: 420 mg / 14 mL (30 mg/mL) Single-dose Vial Pharmacological Class: HER2-Dimerization Inhibitor (Monoclonal Antibody) Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Do not freeze. Primary Clinical Indications Metastatic Breast Cancer (MBC): Indicated for use in combination with Trastuzumab and Docetaxel for patients with HER2-positive MBC who have not received prior anti-HER2 therapy. Neoadjuvant Treatment: For patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen. Adjuvant Treatment: For patients with HER2-positive early breast cancer at high risk of recurrence. Mechanism of Action: The Science of Dimerization Blockade Pertuzumab’s therapeutic efficacy lies in its ability to target the HER2 dimerization domain (Domain II). Prevention of Heterodimerization: Pertuzumab inhibits the ligand-induced pairing of HER2 with other HER receptors, most notably HER3. This pairing is the most potent signaling driver for cancer cell survival. Dual Blockade Synergy: When used with Trastuzumab, which binds to Domain IV, the two antibodies provide a comprehensive “Dual Blockade,“ shutting down both ligand-dependent and ligand-independent growth signals. Antibody-Dependent Cellular Cytotoxicity (ADCC): Pertuzumab marks the cancer cells for destruction by the body’s innate immune system, specifically natural killer (NK) cells. Global Export Excellence: UK, USA, UAE, Australia, & South Africa Ernest Oncology manages the logistical complexities of shipping temperature-sensitive biologicals from India to the world’s most demanding healthcare markets. United Kingdom & London: We supply NHS trusts and private oncology centers in London, adhering to all MHRA biological import protocols and safety standards. United States: Bulk supply for hospital systems and specialty wholesalers seeking verified Indian pharmaceutical exports for advanced HER2+ therapy. Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with fast-track, secure, temperature-monitored shipping. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological import standards. South Africa: Strengthening the African oncology sector with high-quality, cost-effective targeted therapies from GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of oncology injectables and specialized biological products. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Perzumab Injection (Pertuzumab): Targeted HER2-Dimerization Inhibitor – Global Supply by Ernest Oncology In the precision medicine landscape of 2026, Perzumab Injection (containing the active ingredient Pertuzumab) represents a critical breakthrough in the treatment of HER2-positive malignancies. As a humanized monoclonal antibody, Perzumab acts as a HER2-dimerization inhibitor, specifically designed to prevent the pairing of HER2 with other HER receptors, thereby shutting down the aggressive growth signals that drive cancer progression. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Perzumab to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring meticulous cold-chain management and rapid global delivery. Technical Product Profile: Perzumab (Pertuzumab) Perzumab is a biological therapy that targets a different epitope on the HER2 receptor than Trastuzumab, making it an essential component of “dual-blockade“ therapy. Product Specifications Active Ingredient: Pertuzumab Common Strength: 420 mg / 14 mL (30 mg/mL) Single-dose Vial Pharmacological Class: Monoclonal Antibody (HER2-Dimerization Inhibitor) Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Primary Clinical Indications Metastatic Breast Cancer (MBC): Indicated for use in combination with Trastuzumab and Docetaxel for patients with HER2-positive MBC who have not received prior anti-HER2 therapy. Neoadjuvant Treatment: Used as part of a complete treatment regimen for patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer. Adjuvant Treatment: For patients with HER2-positive early breast cancer at high risk of recurrence. Mechanism of Action: Dimerization Blockade Perzumab specifically targets the extracellular dimerization domain (Domain II) of the Human Epidermal Growth Factor Receptor 2 (HER2). Inhibition of Pairing: It prevents HER2 from forming pairs (dimers) with other HER family members (HER1, HER3, and HER4), most notably the HER2-HER3 heterodimer. Signaling Interruption: By blocking dimerization, it inhibits the downstream signaling pathways that lead to cell proliferation and survival. Immune System Recruitment: It induces Antibody-Dependent Cellular Cytotoxicity (ADCC), recruiting the body's immune cells to destroy the tumor. Global Export Expertise: UK, USA, UAE, Australia, & South Africa Ernest Oncology manages the logistical complexities of global pharmaceutical distribution, ensuring that oncology providers have consistent access to high-quality, life-saving biologics. United Kingdom & London: We supply NHS trusts and private oncology centers in London, adhering to all MHRA import guidelines and technical documentation requirements. United States: Bulk supply for hospital systems and specialty wholesalers seeking verified Indian pharmaceutical exports for advanced HER2+ therapy. Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with fast-track, secure, temperature-monitored shipping. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological standards. South Africa: Strengthening the African oncology sector with high-quality, cost-effective targeted therapies from GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of oncology injectables and specialized biological products. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Perjeta Injection (Pertuzumab): Advanced HER2-Dimerization Inhibitor – Global Supply by Ernest Oncology In the precision-driven oncology landscape of 2026, Perjeta Injection (active ingredient Pertuzumab) represents a breakthrough in targeted biological therapy. As a recombinant humanized monoclonal antibody, Perjeta is the first in a class of agents called HER2-dimerization inhibitors (HDIs), specifically designed to work in synergy with Trastuzumab to provide a more comprehensive blockade of HER2 signaling pathways. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Perjeta to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring rigorous cold-chain integrity and rapid logistical execution. Technical Product Profile: Perjeta (Pertuzumab) Perjeta targets a different epitope on the HER2 receptor than Trastuzumab, effectively preventing HER2 from pairing (dimerizing) with other HER receptors (HER1, HER3, and HER4). Product Specifications Active Ingredient: Pertuzumab Concentration: 420 mg / 14 mL (30 mg/mL) Single-dose Vial Pharmacological Class: HER2-Dimerization Inhibitor (Monoclonal Antibody) Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Do not freeze or shake. Primary Clinical Indications Metastatic Breast Cancer (MBC): In combination with Trastuzumab and Docetaxel for patients with HER2-positive MBC who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Neoadjuvant Treatment: For patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen. Adjuvant Treatment: For patients with HER2-positive early breast cancer at high risk of recurrence. Mechanism of Action: Dual HER2 Blockade Perjeta’s unique mechanism involves binding to Domain II of the HER2 extracellular domain. Inhibition of Dimerization: Perjeta specifically inhibits the ligand-dependent HER2-HER3 heterodimerization, which is the most potent signaling pair in the HER family. Complementary Action: While Trastuzumab binds to Domain IV to inhibit ligand-independent signaling, Perjeta blocks Domain II. Together, they provide a “dual blockade“ that more effectively shuts down cancer cell growth signals. ADCC Activation: Like other monoclonal antibodies, Perjeta induces Antibody-Dependent Cellular Cytotoxicity (ADCC) to recruit the immune system to destroy tumor cells. Global Export Expertise: UK, USA, UAE, Australia, & South Africa Ernest Oncology manages the logistical complexities of global pharmaceutical trade, ensuring that oncology providers have consistent access to high-value biological medications. United Kingdom & London: We serve NHS trusts and private oncology centers in London, adhering to all MHRA biological import and safety standards. United States: Bulk supply for hospital systems and specialty wholesalers seeking verified Indian pharmaceutical exports for advanced breast cancer care. Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with validated, temperature-monitored shipping to Abu Dhabi and Dubai. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological frameworks. South Africa: Strengthening the African oncology sector with high-quality, cost-effective targeted therapies from GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of oncology injectables and specialized biological products. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383